Cortexyme, Inc. (CRTX) Financial Analysis & Valuation | Quarter Chart
Cortexyme, Inc. (CRTX)
CRTXPrice: $1.95
Fair Value: 🔒
🔒score
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/II... more
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for ... more
Description
Shares
| Market Cap | $70.45M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Casey Lynch |
| IPO Date | 2019-05-09 | CAGR | — |
| Employees | 55 | Website | www.cortexyme.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CRTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $159.98M | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 0.37 |
| P/CF Ratio | -0.15 | P/FCF Ratio | -0.16 |
| EPS | $-2.96 | EPS Growth 1Y | 12.41% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | 18.23% | ROA | -1.24% |
| ROCE | -3.01% | Current Ratio | 2.92 |
| Quick Ratio | 2.92 | Cash Ratio | 2.07 |
| Debt/Equity | 0.03 | Interest Coverage | — |
| Altman Z Score | -24.87 | Piotroski Score | 1 |